LDC4297

LDC4297, also known as LCD044297, is a potent and selective CDK7 inhibitor. LDC4297 exerts broad-spectrum antiviral activity. LDC4297 inhibits CDK7 in vitro in the nano-picomolar range. CDK7 inhibitor LDC4297 is a promising candidate for further antiviral drug development, possibly offering new options for a comprehensive approach to antiviral therapy. (In Vitro) :LDC4297 (0-10 μM; 6 d) dose-dependently inhibits HCMV replication with an EC50 value of 24.5 nM.LDC4297 (0-10 μM; 4 d) shows anti-proliferative activity to primary cultures of fibroblasts derived from human (HFF) with a GI50 value of 4.5 μM.LDC4297 (20 μM; 12-96 h) shows anti-HCMV activity through a multifaceted mode of action that involves an interference with virus-induced Rb phosphorylation.LDC4297 (0-10 μM; 7 d) shows broad antiviral activities to HCMV, GPCMV, MCMV, HVV-6A, HSV-1, HSV-2, VZV, EBV, HAdV-2, Vaccinia virus, HIV-1 (nl4-3), HIV-1 (4LIG7) and Influenza A virus with EC50 values of 0.02, 0.05, 0.07, 0.04, 0.02, 0.27, 0.06, 1.21, 0.25, 0.77, 1.04, 1.13 and 0.99 μM, respectively. (In Vivo) :LDC4297 (100 mg/kg; p.o. once) shows promising pharmacokinetic analyses.

1453834-21-3

LDC4297 | LDC-4297 | LDC 4297 | LCD044297

>98% (HPLC)

DMSO : ≥ 60 mg/mL; 138.72 mM

CC (C) C (C=NN12) =C1N=C (OC3CNCCC3) N=C2NCC4=CC=CC=C4N5N=CC=C5

C23H28N8O

432.52

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.